Sarepta has struck a $125 million deal to sell a voucher it got with last year’s controversial FDA approval of its new Duchenne drug to Gilead, which will give…

The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences.

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a context with J&J's big-selling Prezista.

VC Versant has pumped $20 million on its own into its newly launched preclinical liver disease upstart Jecure, with its founders coming out from a former…

R&D